Importance of multidrug efflux pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of neisseria gonorrhoeae

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3556-3559

  Golparian, Daniel ^a   Shafer, William M ^b,c   Ohnishi, Makoto ^d   Unemo, Magnus ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; KANAMYCIN; MULTIDRUG RESISTANCE PROTEIN; PENICILLIN DERIVATIVE; SOLITHROMYCIN; SPECTINOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARRIER PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; DRUG EFFECTS; GENE; GENETICS; GONORRHEA; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, MDR; GONORRHEA; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; NEISSERIA GONORRHOEAE;

EID: 84901275120     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00038-14     Document Type: Article

References (39)

1. World Health Organization. 2012. Global incidence and prevalence of selected curable sexually transmitted infections-2008. World Health Organization, Geneva, Switzerland. http://www.who.int/reproductivehealth/ publications/rtis/2008-STI-estimates.pdf (accessed 10 March 2014).
2. Tapsall JW, Ndowa F, Lewis DA, Unemo M. 2009. Meeting the public health challenge of multidrug-And extensively drug-resistant Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 7:821-834. http://dx.doi.org/10.1586/eri.09.63.
3. Unemo M, Nicholas RA. 2012. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 7:1401-1422. http://dx.doi.org/10.2217/fmb.12.117.
4. Bolan GA, Sparling PF, Wasserheit JN. 2012. The emerging threat of untreatable gonococcal infection. N. Engl. J. Med. 366:485-487. http://dx.doi.org/10.1056/NEJMp1112456.
5. Lewis DA. 2010. The gonococcus fights back: is this time a knock out? Sex. Transm. Infect. 86:415-421. http://dx.doi.org/10.1136/sti.2010.042648.
6. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 2010. Two cases of verified clinical failures using internationally recommended firstline cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 15: 19721.
7. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. 2012. High-level cefixime-And ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56:1273-1280. http://dx.doi.org/10.1128/ AAC.05760-11.
8. Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M. 2013. Phenotypic and genetic characterization of the first two cases of extended-spectrumcephalosporin- resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J. Antimicrob. Chemother. 68:1267-1270. http://dx.doi.org/10.1093/jac/dkt034.
9. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. 2013. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 309:163-170. http://dx.doi.org/10.1001/jama.2012.176575.
10. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 16:19792.
11. Chen MY, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G. 2013. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J. Antimicrob. Chemother. 68:1445-1447. http://dx.doi.org/10.1093/jac/dkt017.
12. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55:3538-3545. http://dx.doi.org/10.1128/AAC.00325-11.
13. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J. Antimicrob. Chemother. 67:1858-1860. http://dx.doi.org/10.1093/jac/ dks162.
14. Tomberg J, Unemo M, Davies C, Nicholas RA. 2010. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 49:8062-8070. http://dx.doi.org/10.1021/bi101167x.
15. Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. 2009. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 53:3744-3751. http://dx.doi.org/10.1128/AAC.00304-09.
16. Folster JP, Johnson PJ, Jackson L, Dhulipali V, Dyer DW, Shafer WM. 2009. MtrR modulates rpoH expression and levels of antimicrobial resistance in Neisseria gonorrhoeae. J. Bacteriol. 191:287-297. http://dx.doi.org/10.1128/JB. 01165-08.
17. Ohneck EA, Zalucki YM, Johnson PJ, Dhulipala V, Golparian D, Unemo M, Jerse AE, Shafer WM. 2011. A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in Neisseria gonorrhoeae. mBio 2:e00187-11. http://dx.doi.org/10.1128/mBio.00187-11.
18. Olesky M, Hobbs M, Nicholas RA. 2002. Identification and analysis of amino acid mutations in porin IB that mediate intermediate-level resistance to penicillin and tetracycline in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46:2811-2820. http://dx.doi.org/10.1128/AAC.46.9.2811-2820.2002.
19. Olesky M, Zhao S, Rosenberg RL, Nicholas RA. 2006. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J. Bacteriol. 188: 2300-2308. http://dx.doi.org/10.1128/JB.188.7.2300-2308.2006.
20. Veal WL, Nicholas RA, Shafer WM. 2002. Overexpression of the MtrCMtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. J. Bacteriol. 184:5619-5624. http://dx.doi.org/10.1128/JB.184.20.5619-5624.2002.
21. Zarantonelli L, Borthagaray G, Lee EH, Shafer WM. 1999. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob. Agents Chemother. 43:2468-2472.
22. Rouquette-Loughlin CE, Balthazar JT, Shafer WM. 2005. Characterization of the MacA-MacB efflux system in Neisseria gonorrhoeae. J. Antimicrob. Chemother. 56:856-860. http://dx.doi.org/10.1093/jac/dki333.
23. Rouquette-Loughlin CE, Dunham SA, Kuhn M, Balthazar JT, Shafer WM. 2003. The NorM efflux pump of Neisseria gonorrhoeae and Neisseria meningitidis recognizes antimicrobial cationic compounds. J. Bacteriol. 185:1101-1106. http://dx.doi.org/10.1128/JB.185.3.1101-1106.2003.
24. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. 2009. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63:1142-1151. http://dx.doi.org/10.1093/jac/dkp098.
25. Unemo M, Golparian D, Hellmark B. 2014. First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-Antimicrobial regimens for treatment of gonorrhea Antimicrob. Agents Chemother. 58:624-625. http://dx.doi.org/10.1128/AAC.02093- 13. (Letter.)
26. Hagman KE, Shafer WM. 1995. Transcriptional control of the mtr efflux system of Neisseria gonorrhoeae. J. Bacteriol. 177:4162-4165.
27. Gunn JS, Stein DC. 1996. Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant of Neisseria gonorrhoeae. Mol. Gen. Genet. 251:509-517. http://dx.doi.org/10.1007/ s004380050196.
28. Veal WL, Yellen A, Balthazar JT, Pan W, Spratt BG, Shafer WM. 1998. Loss-of-function mutations in the mtr efflux system of Neisseria gonorrhoeae. Microbiology 144(Pt 3):621-627. http://dx.doi.org/10.1099/00221287-144-3-621.
29. Centers for Disease Control and Prevention (CDC). 2012. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer recommended for treatment of gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590-594.
30. Bignell C, Unemo M, European STI Guidelines Editorial Board. 2013. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int. J. STD AIDS 24:85-92. http://dx.doi.org/10.1177/0956462412472837.
31. Shafer WM, Folster JP, Nicholas RA. 2010. Molecular mechanisms of antibiotic resistance expressed by the pathogenic Neisseria, p 245-268. In Genco CA, Wetzler L (ed), Neisseria: molecular mechanisms of pathogenesis. Caister Academic Press, Norfolk, United Kingdom.
32. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM. 1995. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 141: 611-622. http://dx.doi.org/10.1099/13500872-141-3-611.
33. Shafer WM, Qu X, Waring AJ, Lehrer RI. 1998. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc. Natl. Acad. Sci. U. S. A. 95:1829-1833. http://dx.doi.org/10.1073/pnas.95.4.1829.
34. Jerse AE, Sharma ND, Simms AN, Crow ET, Snyder LA, Shafer WM. 2003. A gonococcal efflux pump system enhances bacterial survival in a female mouse model of genital tract infection. Infect. Immun. 71:5576-5582. http://dx.doi.org/10.1128/IAI.71.10.5576-5582.2003.
35. Warner DM, Folster JP, Shafer WM, Jerse AE. 2007. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J. Infect. Dis. 196:1804-1812. http://dx.doi.org/10.1086/522964.
36. Warner DM, Shafer WM, Jerse AE. 2008. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol. Microbiol. 70:462-478. http://dx.doi.org/10.1111/j.1365-2958.2008.06424.x.
37. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès JM. 2007. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 59:1223-1229. http://dx.doi.org/10.1093/jac/ dkl493.
38. Lomovskaya O, Bostian KA. 2006. Practical applications and feasibility of efflux pump inhibitors in the clinic-A vision for applied use. Biochem. Pharmacol. 71:910-918. http://dx.doi.org/10.1016/j.bcp.2005.12.008.
39. Pagès JM, Masi M, Barbe J. 2005. Inhibitors of efflux pumps in Gramnegative bacteria. Trends Mol. Med. 11:382-389. http://dx.doi.org/10.1016/j. molmed.2005.06.006.